Business Wire

CA-ADTRAN

22.3.2024 14:01:28 CET | Business Wire | Press release

Share
Adtran FSP 3000 OLS plays key role in OIF’s largest-ever demo at OFC

Adtran today announced that it’s playing a key role in the Optical Internetworking Forum’s (OIF) most extensive multi-vendor interoperability demo to date, held at the Optical Fiber Communication Conference and Exhibition (OFC). Central to the showcase is Adtran’s FSP 3000 open line system (OLS), which delivers 400Gbit/s OpenZR+ transceiver interoperability across a 1,000km link. The OLS features advanced automation and optimization for maximum performance and user-friendly operation. Involving 47 member companies, the demo marks a major milestone in open networking and highlights the commitment of the OIF community to driving the future of high-performance, efficient and scalable network solutions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240322753779/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Adtran’s FSP 3000 OLS is playing a central role in the OIF’s biggest interoperability demo to date. (Photo: Business Wire)

“Interoperability continues to be at the heart of our vision for the future of optical networking. This year, by showcasing our FSP 3000 OLS’s capacity for 400Gbit/s OpenZR+ transceiver interoperability over regional distances, we’re pushing the boundaries of end-to-end network performance,” said Stephan Neidlinger, VP of global business development at Adtran. “Together with our fellow industry innovators at the OIF, we’re spotlighting what can be achieved when we unite behind intelligent, open architectures. This shared dedication to supporting multi-vendor environments will ensure superior network performance and new levels of flexibility for our customers.”

The demo uses Adtran’s FSP 3000 OLS to interconnect 400Gbit/s OpenZR+ pluggable transceivers from different suppliers over a bidirectional link that extends up to 1,000km. This comprises eight spans and utilizes Corning’s SMF-28 ULL and Contour fibers. The setup uses compact amplification modules integrating EDFA and Raman amplification, OSC, monitor ports and auto-span equalization. This enables an OLS configuration with a high degree of integration, performance, automation and ease of use. It also features terminal nodes with flexible multi-degree ROADMs for power equalization and scalability. The configuration provides an open hardware platform with programmable interfaces that pave the way for interoperability across various data rates, modulation formats and upgrades to 800Gbit/s transport.

“This demo is a testament to the power of strategic collaboration and technological integration, epitomizing the core principles our FSP 3000 OLS was built upon: openness, scalability and cutting-edge performance. Through concerted efforts with our OIF partners, from renowned component manufacturers to key industry players, we’re crafting solutions that will provide the adaptability and optical prowess our customers need for the networking challenges they face,” commented Ryan Schmidt, GM of optical transport at Adtran. “By focusing on customized solutions and embracing an ecosystem-wide approach, Adtran is not only tackling current network complexities but also setting the stage for future advancements, ensuring that our customers will always stay ahead of the game.”

About the OIF demo

OIF to Showcase Interoperability at OFC 2024 with Nearly 50 Member Companies Collaborating to Address Unprecedented Demand for Next-Generation Network Solutions.

OIF’s interoperability demonstration at OFC 2024 will feature 47 member companies showcasing breakthrough solutions in speed, power and density to meet the growing demands of next-generation data center networking, AI/ML and disaggregation applications. See the solutions in 800ZR, 400ZR and OpenZR+ optics, Energy Efficient Interfaces (EEI) & Co-Packaging, Common Electrical I/O (CEI) channels and Common Management Interface Specification (CMIS) implementations that are playing a pivotal role in shaping the industry for the next decade. Experience these live and interactive demonstrations at booth #1323. For more information, visit: www.oiforum.com/meetings-events/oif-ofc-2024.

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by
ADTRAN Holdings, Inc.
www.adtran.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240322753779/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye